4.4 Article

Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe Results From 3 EUROASPIRE Surveys, 1999-2013

期刊

GLOBAL HEART
卷 12, 期 4, 页码 315-+

出版社

UBIQUITY PRESS LTD
DOI: 10.1016/j.gheart.2015.11.003

关键词

-

资金

  1. European Society of Cardiology
  2. Swedish Heart and Lung Foundation
  3. Polish Ministry of Science and Higher Education [20062009]
  4. National Science Centre [DEC-2011/03/B/N27/06101]
  5. Internal Grant Agency, Ministry of Health, Czech Republic [NT 13186]
  6. Servier
  7. Merck Sharp and Dohme
  8. Sanofi-Aventis
  9. Menarini
  10. AstraZeneca
  11. Merck Sharp and Dohme Sweden
  12. Fondation Plan Alzheimer
  13. Alzprotect
  14. Total
  15. Roche
  16. Daichi Sankyo
  17. Genoscreen
  18. Euro Heart Survey
  19. Bristol-Myers Squibb
  20. Pfizer (EUROASPIRE II)
  21. GlaxoSmithKline
  22. Merck/Schering-Plough
  23. Novartis
  24. Pfizer
  25. Servier (EUROASPIRE III)
  26. Amgen
  27. F. Hoffman-La Roche
  28. Merck Sharp and Dohme (EUROASPIRE IV)
  29. National Institute for Health Research [NF-SI-0508-10312] Funding Source: researchfish

向作者/读者索取更多资源

Background: The EUROASPIRE (European Action on Secondary and Primary Prevention by Intervention to Reduce Events) cross-sectional surveys describe time trends in lifestyle and risk factor control among coronary patients between 1999 and 2013 in Belgium, Czech Republic, Finland, France, Ireland, the Netherlands, Poland, Slovenia, and the United Kingdom as part of the EuroObservational Research Programme under the auspices of European Society of Cardiology. Objectives: This study sought to describe time trends in lifestyle, risk factor control, and the use of evidence-based medication in coronary patients across Europe. Methods: The EUROASPIRE II (1999 to 2000), III (2006 to 2007), and IV (2012 to 13) surveys were conducted in the same geographical areas and selected hospitals in each country. Consecutive patients (<= 70 years) after coronary artery bypass graft, percutaneous coronary intervention, or an acute coronary syndrome identified from hospital records were interviewed and examined >= 6 months later with standardized methods. Results: Of 12,775 identified coronary patients, 8,456 (66.2%) were interviewed. Proportion of current smokers was similar across the 3 surveys. Prevalence of obesity increased by 7%. The prevalence of raised blood pressure (>= 140/90 mm Hg or >= 140/80 mm Hg with diabetes) dropped by 8% from EUROASPIRE III to IV, and therapeutic control of blood pressure improved with 55% of patients below target in IV. The prevalence of low-density lipoprotein cholesterol >= 2.5 mmol/l decreased by 44%. In EUROASPIRE IV, 75% were above the target low-density lipoprotein cholesterol <1.8 mmol/l. The prevalence of self-reported diabetes increased by 9%. The use of evidence-based medications increased between the EUROASPIRE II and III surveys, but did not change between the III and IV surveys. Conclusions: Lifestyle habits have deteriorated over time with increases in obesity, central obesity, and diabetes and stagnating rates of persistent smoking. Although blood pressure and lipid management improved, they are still not optimally controlled and the use of evidence-based medications appears to have stalled apart from the increased use of high-intensity statins. These results underline the importance of offering coronary patients access to modern preventive cardiology programs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据